Literature DB >> 46775

Prophylaxis of varicella in children with neoplastic disease: comparative results with zoster immune plasma and gamma globulin.

C F Geiser, Y Bishop, M Myers, N Jaffe, R Yankee.   

Abstract

The incidence and severity of varicella following a close family contact were evaluated in children with neoplastic diseases who received prophylaxis either with commerical gamma globulin or with zoster immune plasma, as compared to patients who did not receive any prophylaxis. In the untreated group, all 14 patients developed varicella, complicated by 1 case of encephalitis and 2 cases of fatal pneumonia. In the group of 17 patients who received 0.6-1.2 ml/kg body weight of gamma globulin, 16 developed varicella, complicated by pneumonia in 2 cases, with 1 death. In the third group of 27 patients who received 10 ml/kg body weight of zoster immune plasma (ZIP), obtained from healthy adults convalescing from herpes zoster, there were only 8 cases of varicella, all very mild. Thus, prophylaxis with ZIP significantly reduced the incidence of clinical varicella (p less than 0.01) and attenuated the severity of its course.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 46775     DOI: 10.1002/1097-0142(197504)35:4<1027::aid-cncr2820350402>3.0.co;2-9

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  7 in total

1.  Quantitation of antibodies to varicella-zoster virus by immune adherence hemagglutination.

Authors:  C L Wong; S Castriciano; M A Chernesky; W E Rawls
Journal:  J Clin Microbiol       Date:  1978-01       Impact factor: 5.948

2.  Clinical pharmacology: plasma protein binding of drugs.

Authors:  W E Lindup; M C Orme
Journal:  Br Med J (Clin Res Ed)       Date:  1981-01-17

3.  Nosocomial varicella. Part II: suggested guidelines for management.

Authors:  G F Hayden; J D Meyers; R E Dixon
Journal:  West J Med       Date:  1979-04

4.  Nosocomial varicella. Part I: outbreak in oncology patients at a children's hospital.

Authors:  J D Meyers; M B MacQuarrie; T C Merigan; M H Jennison
Journal:  West J Med       Date:  1979-03

5.  Clinical use of blood, blood components and blood products.

Authors:  M A Blajchman; F A Shepherd; R A Perrault
Journal:  Can Med Assoc J       Date:  1979-07-07       Impact factor: 8.262

6.  Varicella zoster immune globulin (VARIZIG) administration up to 10 days after varicella exposure in pregnant women, immunocompromised participants, and infants: Varicella outcomes and safety results from a large, open-label, expanded-access program.

Authors:  Myron J Levin; Jennifer M Duchon; Geeta K Swamy; Anne A Gershon
Journal:  PLoS One       Date:  2019-07-03       Impact factor: 3.240

7.  Varicella zoster immune globulin (human) (VARIZIG) in immunocompromised patients: a subgroup analysis for safety and outcomes from a large, expanded-access program.

Authors:  Hayley Gans; Roy F Chemaly
Journal:  BMC Infect Dis       Date:  2021-01-11       Impact factor: 3.090

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.